Bildkälla: Stockfoto

Alzinova: Short comment on yesterday’s aducanumab news - Redeye

Redeye leaves a short comment on the EMA’s negative trend vote on Biogen’s aducanumab and what it means for Alzinova.

Redeye leaves a short comment on the EMA’s negative trend vote on Biogen’s aducanumab and what it means for Alzinova.
Börsvärldens nyhetsbrev
ANNONSER